Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Associations of high HDL cholesterol level with all-cause mortality in patients with heart failure complicating coronary heart disease.

Cai A, Li X, Zhong Q, Li M, Wang R, Liang Y, Chen W, Huang T, Li X, Zhou Y, Li L.

Medicine (Baltimore). 2016 Jul;95(28):e3974. doi: 10.1097/MD.0000000000003974.

2.

Heart Failure: Diagnosis, Management and Utilization.

Inamdar AA, Inamdar AC.

J Clin Med. 2016 Jun 29;5(7). pii: E62. doi: 10.3390/jcm5070062. Review.

3.

Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.

Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A.

Ther Clin Risk Manag. 2016 Jun 3;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016. Review.

4.
5.

Comparative Effects of Statin Therapy versus Renin-Angiotensin System Blocking Therapy in Patients with Ischemic Heart Failure Who Underwent Percutaneous Coronary Intervention.

Won J, Hong YJ, Jeong MH, Park HJ, Kim MC, Kim WJ, Kim HK, Sim DS, Kim JH, Ahn Y, Cho JG, Park JC.

Chonnam Med J. 2016 May;52(2):128-35. doi: 10.4068/cmj.2016.52.2.128. Epub 2016 May 20.

6.

All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.

De Caterina R, Salvatore T, Marchioli R.

Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun.

7.

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.

Henry CA, Lyon RA, Ling H.

Vasc Health Risk Manag. 2016 Apr 19;12:163-9. doi: 10.2147/VHRM.S82387. eCollection 2016. Review.

8.

Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ 3rd, Caraballo PJ.

J Gen Intern Med. 2016 May;31(5):502-8. doi: 10.1007/s11606-015-3583-0. Epub 2016 Feb 5.

PMID:
26850412
9.

Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-γ/Adiponectin Signalling.

Antonopoulos AS, Margaritis M, Verheule S, Recalde A, Sanna F, Herdman L, Psarros C, Nasrallah H, Coutinho P, Akoumianakis I, Brewer AC, Sayeed R, Krasopoulos G, Petrou M, Tarun A, Tousoulis D, Shah AM, Casadei B, Channon KM, Antoniades C.

Circ Res. 2016 Mar 4;118(5):842-55. doi: 10.1161/CIRCRESAHA.115.307856. Epub 2016 Jan 21.

10.

Effects of Statin Therapy on Clinical Outcomes of Survivors of Acute Myocardial Infarction with Severe Systolic Heart Failure.

Woo JS, Hwang SJ, Kim HS, Kim JB, Kim WS, Kim KS, Jeong MH, Kim W; Korea Acute Myocardial Infarction Registry Investigators.

PLoS One. 2015 Dec 11;10(12):e0144602. doi: 10.1371/journal.pone.0144602. eCollection 2015.

11.

Statin therapy for heart failure: to prescribe or not?

Huang XS, Zhao SP.

J Thorac Dis. 2015 Oct;7(10):1702-3. doi: 10.3978/j.issn.2072-1439.2015.10.49. No abstract available.

12.

The use of statins in patients with heart failure: more questions than answers.

Westman PC, Lipinski MJ.

J Thorac Dis. 2015 Oct;7(10):1687-90. doi: 10.3978/j.issn.2072-1439.2015.10.47.

13.

Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes.

Kishimoto I, Makino H, Ohata Y, Tamanaha T, Tochiya M, Anzai T, Kusano K, Noguchi T, Yasuda S, Ogawa H.

BMJ Open Diabetes Res Care. 2015 Oct 29;3(1):e000137. doi: 10.1136/bmjdrc-2015-000137. eCollection 2015.

14.

Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.

Reed SD, Neilson MP, Gardner M, Li Y, Briggs AH, Polsky DE, Graham FL, Bowers MT, Paul SC, Granger BB, Schulman KA, Whellan DJ, Riegel B, Levy WC.

Am Heart J. 2015 Nov;170(5):951-60. doi: 10.1016/j.ahj.2015.08.015. Epub 2015 Aug 20.

PMID:
26542504
15.

The effect of statins on average survival in randomised trials, an analysis of end point postponement.

Kristensen ML, Christensen PM, Hallas J.

BMJ Open. 2015 Sep 24;5(9):e007118. doi: 10.1136/bmjopen-2014-007118. Review.

16.

Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.

Wang HJ, Park JY, Kwon O, Choe EY, Kim CH, Hur KY, Lee MS, Yun M, Cha BS, Kim YB, Lee H, Kang ES.

Autophagy. 2015 Nov 2;11(11):2089-2101.

17.

LDL electronegativity index: a potential novel index for predicting cardiovascular disease.

Ivanova EA, Bobryshev YV, Orekhov AN.

Vasc Health Risk Manag. 2015 Aug 28;11:525-32. doi: 10.2147/VHRM.S74697. eCollection 2015. Review.

18.

The role of statins in chronic heart failure.

Szyguła-Jurkiewicz B, Szczurek W, Król B, Zembala M.

Kardiochir Torakochirurgia Pol. 2014 Sep;11(3):301-5. doi: 10.5114/kitp.2014.45681. Epub 2014 Sep 28.

19.

Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T.

PLoS One. 2015 Aug 19;10(8):e0133970. doi: 10.1371/journal.pone.0133970. eCollection 2015.

20.

Myopathy in older people receiving statin therapy: a systematic review and meta-analysis.

Iwere RB, Hewitt J.

Br J Clin Pharmacol. 2015 Sep;80(3):363-71. doi: 10.1111/bcp.12687. Epub 2015 Jul 22. Review.

Items per page

Supplemental Content

Write to the Help Desk